Weight loss pills(CP00078.US)

Eli Lilly plans to spend $3.5 billion at its Pennsylvania plant in the United States to produce the next generation of weight loss drugs

Eli Lilly Announces Major Manufacturing Expansion Across Multiple U.S. States

Eli Lilly and Company has announced a major expansion of its U.S. manufacturing operations, including a new facility in Lehigh Valley, Pennsylvania. This multi-billion dollar investment aims to create thousands of jobs and enhance access to weight-loss treatments. The initiative is part of Lilly's commitment to invest over $50 billion in U.S. manufacturing since 2020, with new sites in several states and expansions in Puerto Rico and Indianapolis. The company also acquired a manufacturing site in Wisconsin, emphasizing innovation and domestic supply.

Eli Lilly to build $3.5 billion Pennsylvania plant in US manufacturing push

Eli Lilly announced plans to build a $3.5 billion pharmaceutical manufacturing plant in Pennsylvania, aimed at producing injectable weight-loss drugs, including retatrutide. This facility, expected to create at least 850 jobs, is part of Lilly's strategy to expand U.S. production amid potential import tariffs. Construction is set to begin in 2026, with operations starting in 2031. This investment marks the largest by a life sciences company in Pennsylvania's history, reflecting a broader trend among pharmaceutical firms to enhance domestic manufacturing capabilities.

Amgen Inc. Enters into A Termination Agreement with Kyowa Kirin Co., Ltd

Amgen Inc. has entered into a Termination Agreement with Kyowa Kirin Co., Ltd. to terminate their License and Collaboration Agreement from June 1, 2021. This termination will take effect upon receiving regulatory approval. The details of the Termination Agreement are outlined in Exhibit 10.1, which is referenced for completeness.

Record $2.5B Sector Start Spotlights Clinical Oncology Plays

The global oncology market is projected to reach $668.26 billion by 2034, driven by innovative therapies like CAR T cell therapy, which is expected to grow at 31% annually. Oncolytics Biotech Inc. is enhancing its leadership team to advance its cancer treatment, pelareorep, through late-stage trials. Recent hires include John McAdory and Yujun Wu, who bring extensive oncology trial experience. The company has shown promising results in colorectal and anal cancers, significantly outperforming traditional treatments. Additionally, Amgen has acquired Dark Blue Therapeutics to bolster its oncology research.